There are 2789 resources available
1020P - MPT-0118 a clinical drug candidate to assess Treg reprogramming via MALT1 blockade
Presenter: Peter Keller
Session: ePoster Display
1021P - Long non-coding RNAs influence cancer immunotherapy efficacy through regulating T-cell infiltration and activity or tumor antigenicity
Presenter: Anlin Li
Session: ePoster Display
835P - Enhancement of the International Prognostic Index with hematologic parameters: A new prognostic model for diffuse large B-cell lymphoma treated with R-CHOP
Presenter: Haizhu Chen
Session: ePoster Display
836P - Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: A Hong Kong population-based study
Presenter: Shing Fung Lee
Session: ePoster Display
837P - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience
Presenter: Salman Soomar
Session: ePoster Display
839P - Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US
Presenter: Patrick Connor Johnson
Session: ePoster Display
840P - Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Presenter: Yuan-Kai Shi
Session: ePoster Display
841P - IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Presenter: Keyu Li
Session: ePoster Display
842P - Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models
Presenter: Alberto Arribas
Session: ePoster Display